A growing momentum for earlier treatment of psoriasis has the potential to improve outcomes with oral therapies and biologics ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2024 annual results as of 31 December 2024. Financial ...

Several observational studies with biologics other than IL-23 inhibitors have suggested that it might be possible to prevent patients with plaque psoriasis from progressing to psoriatic arthritis ...

The condition is “high-risk” plaque, once narrowly defined as plaque built up in the arteries that is likely to rupture, possibly leading to an acute heart attack or sudden cardiac death.

Ixekizumab maintained a favorable safety and efficacy profile across psoriasis subtypes, including generalized pustular psoriasis (GPP), psoriasis vulgaris, psoriatic arthritis, and erythrodermic ...

Results from multiple Phase III trials of Icotrokinra in moderate-to-severe plaque psoriasis and a Phase IIb trial in ulcerative colitis successfully met all primary endpoints. Johnson & Johnson’s ...

While the Big Pharma didn’t drill down into the data for the Iconic-Advance 1&2 studies, the company did use the conference to reinforce the findings from a previous phase 3 plaque psoriasis win ...

Late-stage data also showed that Johnson & Johnson’s icotrokinra was superior to Bristol Myers Squibb’s Sotyktu at clearing skin and easing symptom severity in patients with plaque psoriasis. Johnson ...

Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with investigational icotrokinra achieved completely clear skin (IGA 0) at Week 24 in Phase 3 ICONIC-LEAD Topline results ...

Once-daily ICP-488 significantly improved PASI scores in patients with plaque psoriasis compared with placebo at week 12. The safety profile of ICP-488 was similar to placebo. ORLANDO — A once ...

ESK-001, a tyrosine kinase 2 inhibitor, may be a promising new oral treatment for plaque psoriasis. Patients taking ESK-001 twice daily maintained skin clearance up to a year. ORLANDO — Patients ...

Johnson & Johnson’s icotrokinra breaks that mold, and in conjunction with the presentation of positive results from a phase 3 trial, the company announced that today it was planning to launch a ...